The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): Rationale, design, and baseline patient characteristics

Journal of Cardiac Failure

Volumn 10, Issue 2, 2004, Pages 101-112

  Massie, Barry M ^a   Krol, William F ^b   Ammon, Susan E ^b   Armstrong, Paul W ^b   Cleland, John G ^b   Collins, Joseph F ^b   Ezekowitz, Michael ^b   Jafri, Syed M ^b   O'Connor, Christopher M ^b   Packer, Milton ^b   Schulman, Kevin A ^b   Teo, Koon ^b   Warren, Stuart ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

anticoagulation; antiplatelet therapy; aspirin; clinical trial; clopidogrel; Heart failure; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE; WARFARIN;

ANAMNESIS; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOPPLER FLOWMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; LABORATORY TEST; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; QUALITY OF LIFE; SIDE EFFECT; SINUS RHYTHM; STROKE;

ADULT; AGED; ANTICOAGULANTS; ASPIRIN; EMBOLISM; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RESEARCH DESIGN; TICLOPIDINE; WARFARIN;

EID: 2942535061     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2004.02.006     Document Type: Article

References (51)

1. Anderson G.M., Hull G. The use of dicumarol as an adjunct to the treatment of congestive heart failure. South Med J. 41:1948;365-372
2. Wishart J.H., Chapman C.B. Dicumarol therapy in congestive heart failure. N Engl J Med. 239:1948;702-704
3. Harvey W.P., Finch C.A. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med. 242:1950;208-211
4. Griffith G.C., Stragnell R., Levinson D.C. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med. 37:1952;867-887
5. Segal J., Stapleton J., McClellan J., Waller B.F., Harvey W.P. Idiopathic cardiomyopathy: clinical features, prognosis, and therapy. Curr Probl Cardiol. 3:1978;1-49
6. Fuster V., Gersh B.J., Guiliani E.R., Tajik A., Brandenberg R., Frye R. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 47:1981;525-531
7. Kyrl P.A., Korninger C., Gossinger H., Glogar D., Lechner K., Niessner H., et al. Prevention of arterial and pulmonary embolism by oral anticoagulation in patients with dilated cardiomyopathy. Thromb Haemost. 54:1985;521-523
8. Cohn J.N., Benedict C.R., LeJemtel T.H. Risk of thromboembolism in left ventricular dysfunction. SOLVD. [abstract] Circulation. 86:(Suppl I):1992;I-252
9. Dries D.L., Rosenberg Y.D., Waclawiw M.A., Domanski M.J. Ejection fraction and the risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm. J Am Coll Cardiol. 29:1997;1074-1080
10. Dunkman W.B., Johnson G.R., Carson P.E., Bhat G., Farrel L., Cohn J.N. Incidence of thromboembolic events in congestive heart failure. Circulation. 87:(Suppl VI):1993;VI-94-VI-101
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy on antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Int Med. 1994;1449-1457
12. Ciaccheri M., Castelli G., Cecchi F., Nannini M., Santoro G., Troiani V., et al. Lack of correlation between intracavitary thrombosis detected by cross sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J. 62:1989;26-29
13. Katz S.D. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk? J Cardiovascular Risk. 2:1995;97-102
14. Cioffi G., Pozzoli M., Forni G., Franchini M., Opasich C., Cobelli F., et al. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J. 17:1996;1381-1389
15. Cleland J.G.F. Anticoagulant and Antiplatelet therapy in heart failure. Curr Opin Cardiol. 12:1997;276-287
16. Massie B.M., Cleland J.G.F., Armstrong P.W., Packer M., Poole-Wilson P.A., Ryden L. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. J Cardiac Fail. 4:1998;3-8
17. Baker D.W., Wright R.F.L. Management of heart failure Part IV. Anticoagulation for patient with heart failure due to left ventricular systolic dysfunction. JAMA. 272:1994;1614-1618
18. Lip G.Y., Gibbs C.R. Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. Quart J Med. 2002;451-459
19. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol. 38:2001;2101-2113
20. Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:2001;1527-1560
21. Jafri S.M., Cleland J., Massie B. Is there a role for warfarin or aspirin therapy in heart failure? Heart Failure Rev. 1:1996;271-276
22. Garg R.K., Gheorghiade M., Jafri S.M. Antiplatelet and anticoagulant therapy in the prevention of thrombemboli in chronic heart failure. Prog Cardiovasc Dis. 41:1998;225-236
23. Lip G.Y.H., Gibbs C.R. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 33:1999;1424-1426
24. Davis C.J., Gurbel P.A., Gattis W.A., Fuzaylov S.Y., Nair G.V., O'Connor C.M., et al. Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. Int J Cardiol. 75:2000;15-21
25. Uretsky B.F., Thygesen K., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 102:2000;611-616
26. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 119:(Suppl):2001;1S-370S
27. Antiplatelet Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 324:2002;71-86
28. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. WARIS I and ASPECT I. N Engl J Med. 347:2002;969-974
29. Van Es R.F., Jonker J.J., Verheugt F.W., Deckers J.W., Grobbee D.E. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 360:2002;109-113
30. Al-Khadra A.S., Salem D.N., Rand W.M., Udelson J.E., Smith J.J., Konstam M.A. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 31:1998;419-425
31. Al-Khadra A.S., Salem D.N., Udelson J.E., Rand W.M., Smith J.J., Konstam M.A. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 31:1998;749-753
32. Teerlink J.R., Massie B.M. The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers. Am Heart J. 138:1999;193-197
33. Massie B.M., Teerlink J.R. Interaction between aspirin and angiotensin-converting enzyme inhibitors: real or imagined. Am J Med. 109:2000;431-433
34. Nguyen K.N., Aursnes I., Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative North Scandinavian Enalapril Survival Study II. Am J Cardiol. 79:1997;115-119
35. Guazzi M., Brambilla R., Reina G., Tumminello G., Guazzi M.D. Aspirin-angiotensin-converting enzyme inhibitor co-administration and mortality in patients with heart failure. A dose-related adverse effect of aspirin. Arch Intern Med. 163:2003;1574-1579
36. Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol. 35:2000;1808-1812
37. Mahé I., Meune C., Diemer M., Caulin C., Bergmeann J.-F. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drug Safety. 24:2001;167-182
38. Stys T., Wawson W.E., Smaldone G.C., Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med. 160:2000;1409-1413
39. Latini R., Tognoni G., Maggioni A.P., Baigent C., Braunwald E., Chen Z.-M., et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. J Am Coll Cardiol. 35:2000;1801-1807
40. Teo K.K., Yusuf S., Pfeffer M., Kober L., Hall A., Pogue J., et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 360:2002;1037-1043
41. Dzau V.J., Packer M., Lilly L.S., Swartz S.L., Hollenberg N.K., Williams G.H. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 310:1984;347-352
42. Hall D., Zeitler H., Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 20:1992;1549-1555
43. Spaulding C., Charbonnier B., Cohen-Solal A., Juilliere Y., Kromer E.P., Benhamda K., et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril. Circulation. 98:1998;757-765
44. Baur L.H., Schipperheyn J.J., van der Laarse A., Souverijn J.H., Frolich M., de Groot A., et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J. 73:1995;227-235
45. Jeserich M., Pape L., Just H., Hornig B., Kupfer M., Munzel T., et al. Effect of long-term angiotensin inhibition on vascular function in patients with chronic congestive heart failure. Am J Cardiol. 76:1995;1079-1082
46. Davie A.P., Love M.P., McMurray J.J. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther. 67:2000;530-537
47. Jones C.G., Cleland J.G.F. Meeting report: the LIDO, HOPE, MOXCON and WASH studies. Eur J Heart Fail. 1:1999;425-431
48. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 348:1996;1329-1339
49. Coumadin Aspirin Reinfarction Study (CARS) Investigator. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet. 350:1997;389-396
50. Fiore L.D., Ezekowitz M.D., Brophy M.T., Lu D., Sacco J., Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 105:2002;557-563
51. Brooks R.G. EuroQoL - the current state of play. Health Policy. 37:1996;53-72